Prometheus Biosciences Long Term Debt

Prometheus Biosciences (RXDX) currently reports a long-term debt of $26M as of March 2023. That compares with $14M in the prior-year period — up 89.2% year over year. Use the charts on this page to explore Prometheus Biosciences's long-term debt history and peer comparisons.

Prometheus Biosciences's long-term debt increased from $14M to $26M — a 89.2% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prometheus Biosciences reported $26M in long-term debt as of March 2023. That compares with $14M in the prior-year period — up 89.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Prometheus Biosciences, and consider following RXDX for alerts when major investors trade the stock.

Prometheus Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RXDX with unrelated industries.